When health sciences and regenerative medicine company Cardium Therapeutics made their presentation recently at the Biotech Showcase Conference in San Francisco, they summarized their unique collection of technology platforms, detailing respective market potential and plans for the future for associated … Continue reading →

Today before the opening bell, Cardium Therapeutics announced it has entered a distribution agreement with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, including the Veterans Administration (VA) healthcare system and military hospitals. An … Continue reading →

When Cardium Therapeutics recently acquired To Go Brands, a San Diego based nutraceuticals developer, it was a major expansion of Cardium’s original Medpodium nutraceutical line, and reflective of the company’s support for the nutraceutical side of their business. Cardium, known … Continue reading →

A major part Cardium’s product candidate portfolio, and the company’s overall strategy, is Excellagen, an acellular biological modulator for advanced wound care management. Cardium’s strategic goal is to develop a portfolio of medical product candidates at various stages of development … Continue reading →

Nutraceuticals developer To Go Brands, recently acquired by health sciences company Cardium Therapeutics, is focused on bringing 100% natural nutrition to people on the go, which includes just about everyone. Their products are designed for easy mixing with water, juices, … Continue reading →

In October of 2012, Cardium Therapeutics, a health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative health products, acquired To Go Brands, a developer of easy-to-use nutraceuticals. To Go Brands products are known for … Continue reading →

Excellagen, Cardium’s FDA-cleared highly-refined fibrillar collagen-based topical gel designed to facilitate wound care management for diabetic ulcers and many other types of wounds, has been the center of much of Cardium’s recent activity. The product was selected by Podiatry Today, … Continue reading →

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, today announced it was on the winning side of a patent decision made in Europe. This decision resolved a long-standing competition between Cardium and its licensor the University of California, … Continue reading →

Cardium Therapeutics, a health sciences and regenerative medicine company, today presented financial results for the third quarter, ended September 30, 2012. The company also reported on recent developments, including the acquisition of To Go Brands nutraceutical brand platform, and various … Continue reading →

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, announced this morning that the company will be displaying two Excellagen® poster presentations at the Desert Foot 2012 High Risk Diabetic Foot Conference being held this week in Phoenix, AZ. … Continue reading →